Effect of Human Growth Hormone on Thyroidal Secretion, Radiothyroxine Turnover and Transport in Man

Oliner, Leo; Ballantine, Jerome J.

doi:10.1210/jcem-28-5-603

Cited by 29 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially, Oliner et al. 16 demonstrated decreased binding capacity of thyroxine binding globulin (TBG) and other serum binding proteins after pituitary derived high dose GH therapy, 4–8 mgs/day for 5–15 days, without significant effect on thyroid function in healthy non‐GHD subjects. The decline in binding proteins was accompanied by a decrease in serum albumin and total protein which may have been related to fluid retention.…”

Section: Mechanism Of Hpt Changes With Gh Replacementmentioning

confidence: 99%

The interaction between growth hormone and the thyroid axis in hypopituitary patients

Behan

Monson

Agha

2011

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryAlterations in the hypothalamo-pituitary-thyroid axis have been reported following growth hormone (GH) administration in both adults and children with and without growth hormone deficiency. Reductions in serum free thyroxine (T4), increased tri-iodothyronine (T3) with or without a reduction in serum thyroid-stimulating hormone secretion have been reported following GH replacement, but there are wide inconsistencies in the literature about these perturbations. The clinical significance of these changes in thyroid function remains uncertain. Some authors report the changes are transient and revert to normal after a few months or longer. However, in adult hypopituitary patients, GH replacement has been reported to unmask central hypothyroidism biochemically in 36-47% of apparently euthyroid patients, necessitating thyroxine replacement and resulting in an attenuation of the benefit of GH replacement on quality of life in those who became biochemically hypothyroid after GH replacement. The group at highest risk are those with organic pituitary disease or multiple pituitary hormone deficiencies. It is therefore prudent to monitor thyroid function in hypopituitary patients starting GH therapy to identify those who will develop clinical and biochemical features of central hypothyroidism, thus facilitating optimal and timely replacement.

show abstract

Section: Mechanism Of Hpt Changes With Gh Replacementmentioning

confidence: 99%

The interaction between growth hormone and the thyroid axis in hypopituitary patients

Behan

Monson

Agha

2011

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…These changes in thyroid hormone levels are usually temporary and are thought to be caused by increased T4 to T3 conversion and inhibition of TSH secretion [5]. However, often FT4, T3, and TSH do not show any changes [8,9].…”

Section: Introductionmentioning

confidence: 99%

Low FT4 Concentrations around the Start of Recombinant Human Growth Hormone Treatment: Predictor of Congenital Structural Hypothalamic-Pituitary Abnormalities?

et al. 2018

View full text Add to dashboard Cite

Background: Growth hormone (GH) treatment may unmask central hypothyroidism (CeH). This was first observed in children with GH deficiency (GHD), later also in adults with GHD due to acquired “organic” pituitary disease. We hypothesized that newly diagnosed CeH in children after starting GH treatment for nonacquired, apparent isolated GHD points to congenital “organic” pituitary disease. Methods: Nationwide, retrospective cohort study including all children with nonacquired GHD between 2001 and 2011 in The Netherlands. The prevalence of CeH, hypothalamic-pituitary (HP) abnormalities, and neonatal congenital hypothyroidism screening results were evaluated. Results: Twenty-three (6.3%) of 367 children with apparent isolated GHD were prescribed LT4 for presumed CeH within 2 years after starting GH treatment. Similarly to children already diagnosed with multiple pituitary hormone deficiency, 75% of these 23 had structural HP abnormalities. In children not prescribed LT4, low pre- or post-GH treatment FT4 concentrations were also associated with structural HP abnormalities. Neonatal screening results of only 4 of the 23 children could be retrieved. Conclusion: In children with nonacquired, apparent isolated GHD, a diagnosis of CeH after, or a low FT4 concentration around the start of GH treatment, is associated with congenital structural HP abnormalities, i.e., “organic” pituitary disease. Neonatal values could not be judged reliably.

show abstract

“…The first points to an increase in peripheral conversion of T4 to T3 along with a decreased conversion of T4 to rT3, selectively mediated by GH (Sato et al ., 1977; Grunfeld et al ., 1988; Jørgensen et al ., 1989; Salomon et al ., 1989; Burman et al ., 1996; Portes et al ., 2000). The second suggests an inhibition of TSH release (Cobb et al ., 1981; Grunfeld et al ., 1988) via either an increased somatostatinergic tone or a T3‐negative feedback mechanism within the pituitary, due to increased T3 production from T4 deiodination (Oliner & Ballantine, 1968; Porter et al ., 1973; Sato et al ., 1977; Rezvani et al ., 1981; Cabello & Wrutniak, 1989; Salomon et al ., 1989; Jørgensen et al ., 1994). As an additional hypothesis, still to be verified, GH administration could also affect thyroxine clearance rate or reduce thyroxine uptake from the gastrointestinal tract.…”

mentioning

confidence: 99%

Recombinant hGH replacement therapy and the hypothalamus–pituitary–thyroid axis in children with GH deficiency: when should we be concerned about the occurrence of central hypothyroidism?

Giavoli

Porretti

Ferrante

et al. 2003

Clinical Endocrinology

View full text Add to dashboard Cite

Contrary to that observed in patients with MPHD, rhGH replacement therapy does not induce central hypothyroidism in children with idiopathic isolated GHD, further supporting the view that in children with MPHD, as in adults, GHD masks the presence of central hypothyroidism. Slow growth (in spite of adequate rhGH substitution and normal IGF-I levels) is an important clinical marker of central hypothyroidism, therefore a strict monitoring of thyroid function is mandatory in treated children with MPHD.

show abstract

Effect of Human Growth Hormone on Thyroidal Secretion, Radiothyroxine Turnover and Transport in Man

Cited by 29 publications

References 0 publications

The interaction between growth hormone and the thyroid axis in hypopituitary patients

The interaction between growth hormone and the thyroid axis in hypopituitary patients

Low FT4 Concentrations around the Start of Recombinant Human Growth Hormone Treatment: Predictor of Congenital Structural Hypothalamic-Pituitary Abnormalities?

Recombinant hGH replacement therapy and the hypothalamus–pituitary–thyroid axis in children with GH deficiency: when should we be concerned about the occurrence of central hypothyroidism?

Contact Info

Product

Resources

About